PE 22-28
Also known as: Spadin fragment
Molecular Identifiers
Overview
Neurogenic peptide derived from a spadin fragment. Inhibits the TREK-1 potassium channel, promoting neurogenesis and antidepressant-like effects. Promising research in depression models and neural plasticity.
Peptide fragment — heptapeptide derived from spadin (positions 22-28 of the sortilin propeptide)
Half-life
~2-4 hours
Administration Route
Subcutaneous
Category
Cognitive & Neuroprotective
Mechanism of Action
- TREK-1 potassium channel inhibition
- Promotion of hippocampal neurogenesis
- Antidepressant-like effects in preclinical models
- Improvement of synaptic plasticity
- Modulation of serotonergic signaling
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 100-500 mcg per subcutaneous injection |
| Frequency | Once daily |
| Timing | Morning or early afternoon |
| Duration | 2-4 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Mild headache
- Transient dizziness
- Injection site pain
Presentations & Preparation
Vials of PE 22-28 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on PE 22-28.
Related Peptides
Adamax
100-500 mcg via intranasal or subcutaneous · 1-2 times daily
Cerebrolysin
5-30 ml per injection · Once daily
Cortagen
5-10 mg per day via subcutaneous injection · Once daily
Dihexa
10-20 mg per subcutaneous injection or oral (research) · Once daily
DSIP
100-300 mcg per subcutaneous injection · Once daily
Epithalon
5-10 mg per injection · Once daily or every other day